KORU Medical Systems (KRMD) said late Tuesday it is seeking clearance from the US Food and Drug Administration for the use of its FreedomEDGE infusion system to subcutaneously administer Phesgo therapy for HER2+ breast cancer patients.
The medical technology company said it has filed a premarket notification to the FDA and expects a market entry upon clearance from the regulator.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments